You are here

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma

Authors

  • Lianjun Zhao The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, ChinaClinical Cancer Institute of Nanjing University, Nanjing, China PubMed articlesGoogle scholar articles
  • Yu Ren The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, ChinaClinical Cancer Institute of Nanjing University, Nanjing, China PubMed articlesGoogle scholar articles
  • Guiying Zhang The Comprehensive Cancer Center of Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China PubMed articlesGoogle scholar articles
  • Kelin Zheng The Comprehensive Cancer Center of Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China PubMed articlesGoogle scholar articles
  • Jiayu Wang The Comprehensive Cancer Center of Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China PubMed articlesGoogle scholar articles
  • Huizi Sha The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, ChinaClinical Cancer Institute of Nanjing University, Nanjing, China PubMed articlesGoogle scholar articles
  • Mengke Zhao The Comprehensive Cancer Center of Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, China PubMed articlesGoogle scholar articles
  • Rong Huang The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China PubMed articlesGoogle scholar articles
  • Donglin Kang The Comprehensive Cancer Center of Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, China PubMed articlesGoogle scholar articles
  • Xinyu Su The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China PubMed articlesGoogle scholar articles
  • Yirong Wu The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China PubMed articlesGoogle scholar articles
  • Wangling Zhang The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China PubMed articlesGoogle scholar articles
  • Ruihe Lai Department of Nuclear Medicine of Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China PubMed articlesGoogle scholar articles
  • Lin Li Department of Pathology of Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China PubMed articlesGoogle scholar articles
  • Rui Mei Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China PubMed articlesGoogle scholar articles
  • Yitao Wang Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China PubMed articlesGoogle scholar articles
  • You Tian Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China PubMed articlesGoogle scholar articles
  • Fufeng Wang Geneseeq Research institute, Nanjing Geneseeq Technology Inc, Nanjing, China PubMed articlesGoogle scholar articles
  • Baorui Liu The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, ChinaClinical Cancer Institute of Nanjing University, Nanjing, China PubMed articlesGoogle scholar articles
  • Zhengyun Zou The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, ChinaClinical Cancer Institute of Nanjing University, Nanjing, China PubMed articlesGoogle scholar articles

Citation

Zhao L, Ren Y, Zhang G, et al
Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma
Journal for ImmunoTherapy of Cancer 2024;12:e008611. doi: 10.1136/jitc-2023-008611
Online issue publication 
June 21, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.